Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients
- 1 February 2013
- journal article
- review article
- Published by Informa UK Limited in Emerging Drugs
- Vol. 18 (1), 9-23
- https://doi.org/10.1517/14728214.2013.777427
Abstract
Introduction: The usefulness of anticoagulation in patients with atrial fibrillation (AF) is well known. However, the inherent limitations of vitamin K antagonists (VKAs) have made the development of new oral anticoagulants necessary. Drugs directed against thrombin or the factor Xa are currently available. Areas covered: These molecules, being administered at fixed doses and not requiring laboratory monitoring, overcome one crucial problem associated with the use of VKAs. However, data about the bleeding risk related to the use of these molecules should be further analyzed. Expert opinion: The efficacy of direct anticoagulants (DACs) in AF-related stroke prevention has been considered the primary outcome in all Phase III published trials. On the other hand, the reduction of the bleeding risk is an important goal achieved by the DACs as compared with VKAs. Besides data deriving from randomized trials, when talking about new drugs, the need of evidences from the ‘everyday clinical practice' are often requested. The aim of this literature revision is to report and analyze data from specific subgroups about which little is known. In particular, information about the use of DACs in oncologic patients, in patients receiving concomitant antiplatelet drugs and in the perioperative period is currently lacking. The parallel evaluation of all these data may lead to the identification of clinical and demographical criteria to choose when to switch to DACs.Keywords
This publication has 62 references indexed in Scilit:
- Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research DatabaseBMJ Open, 2012
- Bleeding of New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled TrialsCardiovascular Drugs and Therapy, 2012
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial FibrillationPLOS ONE, 2012
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary InterventionJournal of the American College of Cardiology, 2011
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of interventionAnnals of Medicine, 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationCirculation, 2011
- Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolJournal of Thrombosis and Thrombolysis, 2011
- Working after a stroke: Survivors' experiences and perceptions of barriers to and facilitators of the return to paid employmentDisability and Rehabilitation, 2007
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002